Message Font: Serif | Sans-Serif
No. of Recommendations: 1
A few random thoughts, as long as I'm here (this is stuff you prolly already knew)...

Lannett produces generic drugs, and markets them under both their own name and other private labels.

Lannett is a well-established company in the Philadelphia area, but has recently undergone a rebirth of sorts, taking on new management and a new, more aggressive business plan.

The new management works for reasonable salaries (IMHO), and buys and owns stock.

They're a small cap. Last year, they moved from the OTC:BB to the AMEX.

Lannett scores very favorably under the Foolish-8 criteria, and Investor's Business Daily has recently written them up as a result of their very high relative strength score (although RS is a fickle indicator, IMHO)

Small float makes for big (potential) volatility.

Lannett no longer produces the controversial diet supplement ephedrine (sp?), associated with the death of Baltimore Orioles pitcher Steve Bechler earlier this year.

The population is aging while health care costs are rising. Both good for generic drug manufacturers, n'est-ce pas?

Generic phharmaceuticals is an extremely competitive industry.

Small caps are dicey -- they can soar quickly or flounder quickly.

We're still in a bear market.

I look forward to a Foolish discussion of this security!

Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.